GlassScriptPhysician profile
Ramon Hugo Sanchez
NPI 1801194147
$5,089.41
in general payments reported to CMS, 2019-2025
20 companies · $1,154 in 2025
The $1,154 reported for 2025 was more than what 93% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $974 · 2021: $1,221 · 2022: $980 · 2023: $186 · 2024: $371 · 2025: $1,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,711.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,209.01 | 2019-2025 | Breztri, Airsupra |
| Novo Nordisk INC | $696.47 | 2021-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $522.58 | 2021-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $373.84 | 2019-2025 | |
| Watermark Medical, INC. | $256.21 | 2020-2023 | Ares Home Sleep Testing Device |
| Abbvie INC. | $154.72 | 2022-2024 | |
| Ethicon INC. | $147.58 | 2022 | |
| Penumbra, INC. | $140.89 | 2025 | Indigo System |
| Esperion Therapeutics, INC. | $124.99 | 2021 | |
| Abiomed | $123.66 | 2021 | |
| Glaxosmithkline, LLC. | $117.67 | 2021-2022 | |
| Amgen INC. | $79.69 | 2025 | Repatha |
| Curonix LLC | $26.14 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Recor Medical INC | $24.38 | 2024 | Paradise Renal Denervation System |
| Merck Sharp & Dohme LLC | $21.70 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19.84 | 2025 | |
| Allergan, INC. | $19.81 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.14 | 2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $14.09 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.